Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06299930
Status:
COMPLETED
Last Update Posted:
2024-03-08
First Post:
2024-02-14
Brief Title:
Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy Based on Tumor Subtypes in Patients With Early-stage Breast Cancer A Multi-institutional Retrospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neoadjuvant chemotherapy NACT for early-stage breast cancer is associated with an increased risk of locoregional recurrence LRR However few studies have conducted subgroup analyses of patients with various molecular subtypes which are one of the determinant factors for treatments The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1 2004 and Dec 31 2018
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None